These products are aimed at patients with chronic pain, refractory epilepsy, anxiety, cancer, Parkinson's, multiple sclerosis, among other illnesses.
The Khiron Life Sciences Corp. company began selling its first medicinal cannabis-based products in Peru, according to its Country Manager, Luis Márquez. These will be marketed by Farmacia Universal.
“After having successfully completed all the requirements requested by Digemid, and following our alliance with Farmacia Universal, we are making available to patients our first master formulas of cannabis derivatives (CBD), which they will be for sale and can be obtained under medical prescription ”, said the executive.
As it is recalled, last March, the company announced that it was the first private entity to receive licenses for the import and commercialization of medicinal cannabis
These products are aimed at patients with chronic pain, refractory epilepsy, anxiety, cancer, Parkinson's, multiple sclerosis, among other illnesses.
Márquez specified that the formulas will be marketed in two presentations in this first stage. “Both have the scientific support of the company. They come to the country with the aim of improving the lives of thousands of patients who have not been successful with conventional therapies in various pathologies, and guarantee safety and efficacy in the treatment, "he said.
For his part, the general manager of Farmacia Universal , Dolores Guevara, indicated that the alliance with Khiron will make it easier for patients to find these formulas and will provide them with
According to Márquez, the use of medicinal cannabis could benefit more than 2.5 million Peruvians, according to a study carried out by the company.
Khiron Life Sciences is conducting a virtual course on medical cannabis, in partnership with the Tecnológico de Monterrey, which will allow training of some 200 Peruvian doctors.